Key result
Fibrillin-1 derived F1R1 peptide increases in vitro cardiomyocyte proliferation ~3-fold versus controls.
Why the study?
The specific peptide(s) or protein(s) in solubilized cardiac ECM responsible for promoting cardiomyocyte proliferation were unknown.
Does a synthetic peptide derived from fibrillin-1 (residues 55-86) improve cardiomyocyte proliferation in vitro?
Does a synthetic peptide derived from fibrillin-1 (residues 55-86) improve cardiomyocyte proliferation in vitro?
Effect estimate: 2.9 fold change increase
Absolute Event Rate: 27.6% vs 9.5%
A synthetic peptide derived from fibrillin-1 promotes cardiomyocyte proliferation and reduces fibroblast activation in vitro, suggesting potential utility for cardiac tissue engineering and regeneration.
No immediate clinical implications; leaves open whether F1R1 enables cardiac regeneration in vivo.
The development of regenerative strategies to repair the heart is of high importance. Our lab has shown that extracellular matrix derived from decellularized fetal myocardium promotes neonatal cardiomyocyte proliferation in vitro. The goal of this study was to identify specific peptide(s)/protein(s) in solubilized cardiac ECM responsible for this proliferative effect. We hypothesized that isolation and then treatment with one or more small synthetic peptide derived from this source could replicate the cellular response to whole solubilized ECM. Decellularized fetal and adult rat hearts were fractionated by molecular weight using SDS-PAGE and transferred to PVDF membranes. Analysis of cardiomyocytes cultured on the membranes revealed regions of enhanced cardiomyocyte proliferation. Subsequent isolation and proteomic analysis of the protein bands that that correlated with proliferative regions identified fibrillin-1 as the predominant ECM protein associated with these regions of cardiomyocyte proliferation. One region (residues 55-86) of fibrillin-1 was synthesized as a peptide and tested for a direct effect on cardiomyocyte proliferation. Compared to positive and negative controls, as well as scrambled and alkylated versions, this peptide led to 3-4-fold increase in cardiomyocyte proliferation. Analysis of the amino acid sequence demonstrated high homology with latent-TGF-β binding proteins and subsequent experiments showed that the matrikine could also reduce TGF-β induced activation of cardiac fibroblasts. These data suggest that individual peptides derived from soluble ECM could have utility as a novel therapeutic for cardiac tissue engineering and regeneration.
No takes yet. Share an insight, caveat, or question.
Edmunds et al. (2026) studied Cardiac regeneration. F1R1 peptide (fibrillin-1 derived matrikine) vs. Scrambled peptide, alkylated peptide, and negative controls was evaluated on Cardiomyocyte proliferation (% proliferative CMs) (2.9 fold change increase). The fibrillin-1 derived F1R1 peptide led to a 3-4 fold increase in cardiomyocyte proliferation compared to controls, reaching 27.6% proliferative cardiomyocytes after 5 days in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: